China Securities News (reporter Wang Hui) On November 28, a reporter learned that Pfizer Investment Co., Ltd. (hereinafter referred to as "Pfizer") and China Resources Pharmaceutical Business Group Co., Ltd. (hereinafter referred to as "China Resources Pharmaceutical Business") had officially signed a strategic cooperation agreement on November 26, giving full play to their respective strengths, and jointly promoting the commercial operation of four high-quality mature drugs for lung cancer and breast cancer - AROMASIN, IBRANCE, Pharmaceutin RD, XALKORI, to expand patient accessibility.
It is understood that China Resources Pharmaceutical will fully leverage its extensive market coverage system and perfect distribution network advantages to quickly reach a wider range of patient groups with these mature drugs. Pfizer will continue to increase its investment in the field of cancer, deeply cultivate the world's high incidence cancers such as lung cancer, breast cancer, urinary system tumors, blood tumors, and accelerate the research and development of innovative drugs and provide revolutionary treatment programs.
Jean Christophe Pointeau, President of Pfizer China, expressed his hope to expand the accessibility of Pfizer's mature drugs, especially to benefit more patients in remote rural areas. Wu Jianjun, chairman of the commercial board of CR Pharmaceuticals, said that the in-depth cooperation with Pfizer in the field of breast cancer and lung cancer drugs marked the further deepening of the cooperation between the two sides.
At the recently held 7th CIIE, Jean Christophe Pointeau stated that Pfizer will invest $1 billion in China between 2025 and 2030, continuously investing in accelerating innovation, improving diagnostic capabilities and treatment standards, and promoting the development of the local biotechnology industry.